CAPITAL: Optimal subgroup identification via constrained policy tree search. (7th July 2022)

• Record Type: Journal Article
• Authors: Cai, Hengrui; Lu, Wenbin; Marceau West, Rachel; Mehrotra, Devan V.; Huang, Lingkang
• Is Part Of: Statistics in medicine. Volume 41:Number 21(2022)
• Page Start: 4227
• Page End: 4244
• Publication Date: 2022-07-07
• Subjects: constrained policy tree search -- optimal subgroup identification -- personalized medicine; Medical statistics -- Periodicals; Statistique médicale -- Périodiques; Statistiques médicales -- Périodiques; 610.727
• DOI: 10.1002/sim.9507
• Languages: English
• ISSNs: 0277-6715

Abstract

Abstract : Personalized medicine, a paradigm of medicine tailored to a patient's characteristics, is an increasingly attractive field in health care. An important goal of personalized medicine is to identify a subgroup of patients, based on baseline covariates, that benefits more from the targeted treatment than other comparative treatments. Most of the current subgroup identification methods only focus on obtaining a subgroup with an enhanced treatment effect without paying attention to subgroup size. Yet, a clinically meaningful subgroup learning approach should identify the maximum number of patients who can benefit from the better treatment. In this article, we present an optimal subgroup selection rule (SSR) that maximizes the number of selected patients, and in the meantime, achieves the pre‐specified clinically meaningful mean outcome, such as the average treatment effect. We derive two equivalent theoretical forms of the optimal SSR based on the contrast function that describes the treatment‐covariates interaction in the outcome. We further propose a constrained policy tree search algorithm (CAPITAL) to find the optimal SSR within the interpretable decision tree class. The proposed method is flexible to handle multiple constraints that penalize the inclusion of patients with negative treatment effects, and to address time to event data using the restricted mean survival time as the clinically interesting mean outcome. Extensive simulations, comparison studies, and real data applications are conducted to demonstrate the validity and utility of our method.